Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults

Journal of Clinical Psychopharmacology

Volumn 30, Issue 6, 2010, Pages 672-677

  Lenze, Eric J ^a   Goate, Alison M ^a   Nowotny, Petra ^a   Dixon, David ^a   Shi, Peichang ^a   Bies, Robert R ^b   Lotrich, Francis K ^c   Rollman, Bruce L ^c   Shear, M Katherine ^d   Thompson, Paul A ^e   Andreescu, Carmen ^c   Pollock, Bruce G ^f  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e UNIVERSITY OF SOUTH DAKOTA   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

anxiety disorders; genetics; geriatrics; SSRI

Indexed keywords

DNA; ESCITALOPRAM; PLACEBO; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

AGED; AGING; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GENERALIZED ANXIETY DISORDER; GENETIC VARIABILITY; GENOTYPE; GERIATRIC PATIENT; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANXIETY DISORDERS; CITALOPRAM; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 78649385021     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181fc2bef     Document Type: Article

References (33)

1. Bryant C, Jackson H, Ames D. The prevalence of anxiety in older adults: methodological issues and a review of the literature. J Affect Disord. 2008;109(3):233-250.
2. Lenze EJ, Mulsant BH, Shear MK, et al. Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry. 2005;162(1):146-150.
3. Schuurmans J, Comijs H, Emmelkamp PM, et al. A randomized, controlled trial of the effectiveness of cognitive-behavioral therapy and sertraline versus a waitlist control group for anxiety disorders in older adults. Am J Geriatr Psychiatry. 2006;14(3):255-263.
4. Lenze EJ, Rollman BL, Shear MK, et al. Escitalopram for older adults with generalized anxiety disorder: a placebo-controlled trial. JAMA. 2009;301(3):296-303.
5. Benitez CI, Smith K, Vasile RG, et al. Use of benzodiazepines and selective serotonin reuptake inhibitors in middle-aged and older adults with anxiety disorders: a longitudinal and prospective study. Am J Geriatr Psychiatry. 2008;16(1):5-13.
6. Serretti A, Kato M, De Ronchi D, et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007;12(3):247-257.
7. Hu X-Z, Lipsky RH, Zhu G, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet. 2006;78(5):815-826.
8. Lotrich FE, Pollock BG, Ferrell RE. Polymorphism of the serotonin transporter: implications for the use of selective serotonin reuptake inhibitors. Am J Pharmacogenomics. 2001;1(3):153-164.
9. Mrazek DA, Rush AJ, Biernacka JM, et al. SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet. 2009;150B(3):341-351.
10. Lotrich FE, Pollock BG, Kirshner M, et al. Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. J Psychiatry Neurosci. 2008;33(2):123-130.
11. Pollock BG. The pharmacokinetic imperative in late-life depression. J Clin Psychopharmacol. 2005;25(4 suppl 1):S19YS23.
12. First MB, Spitzer RL, Gibbon M. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID), Clinician Version: Administration Booklet. Washington, DC: American Psychiatric Press, Inc; 1996.
13. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-55.
14. Guy W. ECDEU Assessment Manual for Psychopharmacology. Dept. of Health EaWpA, Rev. Ed. Rockville, MD: NIMH; 1976.
15. Meyer TJ, Miller ML, Metzger RL, et al. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28(6):487-495.
16. Wendland JR, Martin BJ, Kruse MR, et al. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry. 2006;11(3):224-226.
17. Foglia JP, Sorisio D, Kirshner M, et al. Quantitative determination of paroxetine in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1997; 693(1):147-151.
18. Huezo-Diaz P, Uher R, Smith R, et al. Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry. 2009;195(1):30-38.
19. Arias B, Catalan R, Gasto C, et al. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol. 2003;23(6):563-567.
20. Zanardi R, Benedetti F, Di Bella D, et al. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol. 2000;20(1):105-107.
21. Beal SL, Sheiner LB. NONMEM Users Guides. NONMEM Project Group. San Francisco, CA: University of California; 1992.
22. Jin Y, Pollock BG, Frank E, et al. The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. J Clin Pharmacol. 2009;49(2):176-184.
23. Sogaard B, MengelH,Roa N, et al. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol. 2005;45(12):1400-1406.
24. Gunthert KC, Conner TS, Armeli S, et al. Serotonin transporter gene polymorphism (5-HTTLPR) and anxiety reactivity in daily life: a daily process approach to gene-environment interaction. Psychosom Med. 2007;69(8):762-768.
25. Durham LK, Webb SM, Milos PM, et al. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl). 2004;174(4):525-529.
26. Hariri AR, Drabant EM, Weinberger DR. Imaging genetics: perspectives from studies of genetically driven variation in serotonin function and corticolimbic affective processing. Biol Psychiatry. 2006;59(10):888-897.
27. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301(5631):386-389.
28. Gotlib IH, Joormann J, Minor KL, et al. HPA axis reactivity: a mechanism underlying the associations among 5-HTTLPR, stress, and depression. Biol Psychiatry. 2008;63(9):847-851.
29. O'Hara R, Schroder CM, Mahadevan R, et al. Serotonin transporter polymorphism, memory and hippocampal volume in the elderly: association and interaction with cortisol. Mol Psychiatry. 2007;12(6): 544-555.
30. Mandelli L, Marino E, Pirovano A, et al. Interaction between SERTPR and stressful life events on response to antidepressant treatment. Eur Neuropsychopharmacol. 2009;19(1):64-67.
31. Hawley LL, Ringo Ho MH, Zuroff DC, et al. Stress reactivity following brief treatment for depression: differential effects of psychotherapy and medication. J Consult Clin Psychol. 2007;75(2): 244-256.
32. Lotrich FE, Bies RR, Smith GS, et al. Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. J Psychopharmacol. 2006;20(suppl 4):33-40.
33. Serretti A, Kato M, Kennedy JL. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J. 2008;8(2):90-100.